Non-classical transpeptidases yield insight into new antibacterials.

Area of Science:

• Microbiology
• Medicinal Chemistry
• Biochemistry

Background:

• Bacterial survival depends on an intact peptidoglycan layer.
• D,D-transpeptidases, inhibited by β-lactams, are historically known to synthesize peptidoglycan.
• Mycobacteria primarily utilize L,D-transpeptidases for peptidoglycan synthesis.

Purpose of the Study:

• To investigate the distinct effectiveness of carbapenems against bacterial pathogens.
• To elucidate the molecular mechanisms of carbapenem inhibition of L,D-transpeptidases.
• To design and synthesize novel carbapenems with potent antibacterial activity.

Main Methods:

• Characterization of molecular mechanisms of L,D-transpeptidase inhibition.
• Synthesis of simplified carbapenem analogs.
• Testing antibacterial activity of novel compounds against Mycobacterium tuberculosis and ESKAPE pathogens.

Main Results:

• Carbapenems inhibit both D,D-transpeptidases and L,D-transpeptidases.
• L,D-transpeptidases are the primary targets for carbapenem activity in mycobacteria.
• Novel simplified carbapenems demonstrated potent antibacterial activity.

Conclusions:

• Carbapenems' broad efficacy stems from dual inhibition of bacterial transpeptidases.
• Targeting L,D-transpeptidases offers a promising strategy for combating mycobacterial infections.
• Development of simplified carbapenems provides new therapeutic options against resistant bacteria.